COVID-19: A trigger of autoimmune diseases.
Arghavan ZebardastAli HasanzadehSeyedeh Arefeh Ebrahimian ShiadehMehdi TouraniYousef YahyapourPublished in: Cell biology international (2023)
The SARS-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19), has spread worldwide and caused a global health emergency. SARS-CoV-2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane-expressed angiotensin-converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS-CoV-2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID-19 may be related to an overabundance of pro-inflammatory cytokines, which results in a "cytokine storm" and acute respiratory distress syndrome. After SARS-CoV-2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain-Barré syndrome, vasculitis, multiple sclerosis, pro-thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID-19 and autoimmune disorders in this article.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- multiple sclerosis
- acute respiratory distress syndrome
- angiotensin converting enzyme
- global health
- angiotensin ii
- public health
- extracorporeal membrane oxygenation
- immune response
- young adults
- systemic lupus erythematosus
- white matter
- case report
- cell cycle arrest
- high intensity
- cell death
- low grade
- small molecule
- protein kinase